ACAM Defends Chelation

[Guest guest]

LAGUNA HILLS, Calif., Aug. 29 /PRNewswire/ -- The mission of the

American

College for Advancement in Medicine (ACAM) is to educate physicians

worldwide

in the most recent research and evidence-based medical treatment modalities

of

Complementary, Alternative and Integrative Medicine (CAIM). For over thirty

years, in addition to other medical treatment modalities and technologies,

ACAM has been training physicians in the appropriate and safe delivery of

Chelation Therapy which has been used successfully for over 3 decades and

involves an intravenous injection of a synthetic amino acid called ethylene

diamine tetra-acetic acid (EDTA) that is approved by the FDA.

With insufficient test results available at this time of the recent sad

death of an autistic UK boy who was receiving this therapy in the United

States, ACAM is not in a position to comment on the circumstances that led

to

this unfortunate incident.

However, it is important to note that IV EDTA is an FDA approved

treatment

for lead toxicity in children and adults, with an excellent track record for

safety. Millions of infusions have been administered over the last 30 +

years, without any deaths being noted, when used in accordance with

established guidelines. These guidelines were developed by experts in the

field, and include the IV administration of Calcium EDTA, and the more

lengthy

IV infusion of Magnesium, Disodium EDTA.

Chelation Therapy has been clinically helpful for many autistic children

who have evidence of heavy metal burdens, and have an impaired ability for

detoxification. In adults, it has been used to treat Arteriosclerotic

Vascular Disease; and other chronic degenerative diseases that may be

associated with heavy metal burdens. In fact, the TACT study (Trial to

Assess

Chelation Therapy), has been in progress, with a goal to assess the efficacy

of Chelation Therapy in close to 2,400 patients. In launching this NIH

sponsored study, the safety of IV EDTA was accepted to have been firmly

established.

ACAM supports the safe and appropriate use of Chelation Therapy. ACAM

is

confident that the use of this treatment, in accordance with established

guidelines, will continue to maintain its excellent safety record.

The American College for Advancement in Medicine (ACAM) was founded in

1973, is a 501 © (6) not-for-profit medical society dedicated to educating

physicians and other health care professionals on the latest findings and

emerging procedures in preventive/nutritional medicine. ACAM represents

over

1,000 physicians in 30 countries. ACAM is the largest and oldest

organization

of its kind in the world dedicated exclusively to serving the educational

needs of the health professionals. ACAM members follow a Code of Ethics and

Rules of Conduct. ACAM holds International Educational Conferences, and the

next meeting will be held November 9-13, 2005 in Anaheim, California. The

Organization also distributes numerous books and studies to its membership

and

thousands of medical professionals.

For further information on upcoming ACAM Educational events visit it's

website at http://www.acam.org.